Bright Minds Biosciences Inc. (CSE:DRUG)

Bright Minds Biosciences Income Statement

Financials in millions CAD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021
Selling, General & Admin	4.62	2.53	1.45	2.2	2.55	2.31
Research & Development	26.18	11.08	1.18	5	12.18	6.31
Operating Expenses	30.8	13.61	2.63	7.2	14.73	8.62
Operating Income	-30.8	-13.61	-2.63	-7.2	-14.73	-8.62
Interest Expense	-0.05	-0.04	-	-	-	-
Interest & Investment Income	4.51	1.52	0.03	-	-	-
Currency Exchange Gain (Loss)	-0.68	0.19	-0.01	0.01	0.01	0.15
Other Non Operating Income (Expenses)	-0.33	-0.29	-0.2	-0.19	-0.24	-0.18
EBT Excluding Unusual Items	-27.35	-12.23	-2.8	-7.37	-14.96	-8.65
Asset Writedown	-	-	-	-	-0	-
Pretax Income	-27.35	-12.23	-2.8	-7.37	-14.96	-8.65
Net Income	-27.35	-12.23	-2.8	-7.37	-14.96	-8.65
Net Income to Common	-27.35	-12.23	-2.8	-7.37	-14.96	-8.65
Shares Outstanding (Basic)	8	7	4	4	2	2
Shares Outstanding (Diluted)	8	7	4	4	2	2
Shares Change (YoY)	42.99%	59.58%	15.87%	50.58%	37.64%	148.42%
EPS (Basic)	-3.46	-1.78	-0.65	-1.98	-6.06	-4.82
EPS (Diluted)	-3.46	-1.78	-0.65	-1.98	-6.06	-4.82
EBIT	-30.8	-13.61	-2.63	-7.2	-14.73	-8.62

Source: S&P Global Market Intelligence. Standard template. Financial Sources.